This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2021 Sep;80(3):323-324.

doi: 10.1016/j.eururo.2021.06.013. Epub 2021 Jul 1.

Defining Resistance to Immune Checkpoint Inhibitors in Urothelial Carcinoma: Insights from PURE-01

Timothy N Clinton¹

Affiliations

PMID: 34218973
DOI: 10.1016/j.eururo.2021.06.013

Editorial

Defining Resistance to Immune Checkpoint Inhibitors in Urothelial Carcinoma: Insights from PURE-01

Timothy N Clinton. Eur Urol. 2021 Sep.

. 2021 Sep;80(3):323-324.

doi: 10.1016/j.eururo.2021.06.013. Epub 2021 Jul 1.

Author

Timothy N Clinton¹

Affiliation

¹ Department of Surgery, Division of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: tclinton88@gmail.com.

PMID: 34218973
DOI: 10.1016/j.eururo.2021.06.013

No abstract available

PubMed Disclaimer

Comment on

Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?
Pederzoli F, Bandini M, Raggi D, Marandino L, Basile G, Alfano M, Colombo R, Salonia A, Briganti A, Gallina A, Montorsi F, Necchi A. Pederzoli F, et al. Eur Urol. 2021 Sep;80(3):319-322. doi: 10.1016/j.eururo.2021.05.018. Epub 2021 May 27. Eur Urol. 2021. PMID: 34053782 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information